Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice

Sena Kim, Sora Lim, Boram Kim, Julie Ritchey, Kiran Vij, Julie Prior, Lynne Marsala, Alyssa Stoner, Feng Gao, Samuel Achilefu, Matthew L. Cooper, John F. DiPersio, Jaebok Choi

Blood (2023) 141 (8): 945–950.

https://doi.org/10.1182/blood.2021012687

Published: 2023

Includes: Supplemental data

Journal Articles

Restoring NK cell functions in AML relapse

Sena Kim, Jaebok Choi

Blood (2022) 140 (26): 2765–2766.

https://doi.org/10.1182/blood.2022018079

Published: 2022

Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 1875–1876.

https://doi.org/10.1182/blood-2022-157214

Published: 2022

Journal Articles

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Kidist Ashami, BA, Sena Kim, PhD, Ravi Vij, MBBS, Julie K. Ritchey, Srikanth Santhanam, PhD, Sora Lim, MS, Sarah Peterson, Matthew Ciorba, MD, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2019) 134 (Supplement_1): 4420.

https://doi.org/10.1182/blood-2019-126167

Published: 2019

Journal Articles

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Karl W. Staser, MD PhD, Matthew L. Cooper, PhD, Jaebok Choi, PhD, Anand Chukka, Kidist Ashami, BA, Jessica Niswonger, Jaehan Park, Byung Ha Lee, PhD, Shunqiang Li, PhD, Amanda F Cashen, MD, Amy Musiek, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 340.

https://doi.org/10.1182/blood-2018-99-119375

Published: 2018

Journal Articles

Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair

Kidist Ashami, BA, Kiran R. Vij, MD, Julie Ritchey, Srikanth Santhanam, PhD, Karl W. Staser, MD PhD, Sora Lim, Sena Kim, Matthew L. Cooper, PhD, Feng Gao, PhD, Matthew Ciorba, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2018) 132 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2018-99-119470

Published: 2018

Journal Articles

An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 844.

https://doi.org/10.1182/blood.V130.Suppl_1.844.844

Published: 2017

Journal Articles

Selective Inhibition of α4β1 Integrin (VLA-4) Mitigates GvHD

Bader Alahmari, MD, Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Julie Ritchey, Bing Wang, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3344.

https://doi.org/10.1182/blood.V128.22.3344.3344

Published: 2016

Journal Articles

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Bing Wang, Julie Ritchey, Bader Alahmari, MD, Matthew Holt, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3353.

https://doi.org/10.1182/blood.V128.22.3353.3353

Published: 2016

Journal Articles

Targeting Alpha 4 Integrin (CD49d) to Reduce GvHD

Bader Alahmari, MBBS, Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2015) 126 (23): 4283.

https://doi.org/10.1182/blood.V126.23.4283.4283

Published: 2015

Journal Articles

A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Mark A. Schroeder, MD, Jaebok Choi, PhD, Matthew L Cooper, PhD, David Schwab, BA CCRP, Sarah Willey, Jingxia (Esther) Liu, PhD, Matthew Holt, Linda Eissenberg, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD, John S. Welch, MD PhD, Keith Stockerl-Goldstein, MD, Camille N. Abboud, MD FACP, Ravi Vij, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1935.

https://doi.org/10.1182/blood.V126.23.1935.1935

Published: 2015

Journal Articles

Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFNγR-/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo

Matthew L Cooper, PhD, Jaebok Choi, PhD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 3828.

https://doi.org/10.1182/blood.V124.21.3828.3828

Published: 2014

Journal Articles

Targeting VLA-4 to Reduce GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Bader Alahmari, MD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 3829.

https://doi.org/10.1182/blood.V124.21.3829.3829

Published: 2014

Journal Articles

Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Iskra Pusic, MD, Jaebok Choi, PhD, Noel Bernabe, Camille N. Abboud, MD, Peter Westervelt, MD, PhD, Ravi Vij, MD, Amanda F Cashen, MD, Geoffrey L. Uy, MD, Keith E. Stockerl-Goldstein, MD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 4638.

https://doi.org/10.1182/blood.V122.21.4638.4638

Published: 2013

Journal Articles

IFNγR Signaling As a Therapeutic Target To Prevent GvHD While Preserving Gvl

Jaebok Choi, PhD, Matthew L Cooper, PhD, Julie Ritchey, Lynne Collins, Julie Prior, David Piwnica-Worms, MD, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 4464.

https://doi.org/10.1182/blood.V122.21.4464.4464

Published: 2013

Journal Articles

Defining The Mechanism Involved In The Inhibition Of GvHD By Azacytidine In Vivo Through The Use Of FoxP3 Diphtheria Toxin Receptor ( Foxp3 DTR ) Donor T Cells

Matthew L Cooper, PhD, Jaebok Choi, PhD, Julie Ritchey, John F. DiPersio, MD, PhD

Blood (2013) 122 (21): 134.

https://doi.org/10.1182/blood.V122.21.134.134

Published: 2013

Journal Articles

Interruption of IFNγR Signaling Results in Altered T Cell Trafficking in Vivo and Abrogation of GvHD While Maintaining a Robust Gvl Response

Jaebok Choi, PhD., Edward Dela Ziga, MD, MPH, Julie Ritchey, Lynne Collins, Julie Prior, Matthew Cooper, PhD, David Piwnica-Worms, MD, PhD, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 455.

https://doi.org/10.1182/blood.V120.21.455.455

Published: 2012

Journal Articles

Use of FoxP3 Diptheria Toxin Receptor ( Foxp3 DTR ) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo

Matthew L Cooper, PhD, Jaebok Choi, PhD., Julie Ritchey, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 4113.

https://doi.org/10.1182/blood.V120.21.4113.4113

Published: 2012

Journal Articles

IFNγR signaling mediates alloreactive T-cell trafficking and GVHD

Jaebok Choi, Edward D. Ziga, Julie Ritchey, Lynne Collins, Julie L. Prior, Matthew L. Cooper, David Piwnica-Worms, John F. DiPersio

Blood (2012) 120 (19): 4093–4103.

https://doi.org/10.1182/blood-2012-01-403196

Published: 2012

Includes: Supplemental data

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice

Restoring NK cell functions in AML relapse

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair

An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies

Selective Inhibition of α4β1 Integrin (VLA-4) Mitigates GvHD

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Targeting Alpha 4 Integrin (CD49d) to Reduce GvHD

A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFNγR-/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo

Targeting VLA-4 to Reduce GvHD

Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

IFNγR Signaling As a Therapeutic Target To Prevent GvHD While Preserving Gvl

Defining The Mechanism Involved In The Inhibition Of GvHD By Azacytidine In Vivo Through The Use Of FoxP3 Diphtheria Toxin Receptor ( Foxp3 DTR ) Donor T Cells

Interruption of IFNγR Signaling Results in Altered T Cell Trafficking in Vivo and Abrogation of GvHD While Maintaining a Robust Gvl Response

Use of FoxP3 Diptheria Toxin Receptor ( Foxp3 DTR ) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo

IFNγR signaling mediates alloreactive T-cell trafficking and GVHD

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only